Century Therapeutics SVP sells $762 in stock

Douglas Carr, the Senior Vice President of Finance & Operations at Century Therapeutics , Inc. (NASDAQ:IPSC), recently reported a sale of company stock, according to a filing with the Securities and Exchange Commission. On March 10, Carr sold 1,240 shares of common stock at a price of $0.615 per share, totaling approximately $762. This transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units.

In a separate transaction on March 11, Carr acquired 95,625 restricted stock units (RSUs) at no cost. Each RSU represents a contingent right to receive one share of Century Therapeutics’ common stock. The RSUs are structured to vest 25% on March 11, 2026, with the remaining 75% vesting quarterly over the following three years, contingent upon Carr’s continued service with the company. With a market capitalization of approximately $51 million, analysts maintain a bullish stance on the stock, with price targets ranging from $4 to $13.

Additionally, Carr was granted stock options, also on March 11, for 95,625 shares at an exercise price of $0.601 per share. These options are set to vest 25% on March 11, 2026, with the remainder vesting in equal monthly installments over three years, subject to continued service. InvestingPro data shows the company’s overall financial health score is currently rated as ’Weak,’ with additional insights available to subscribers. The company is scheduled to report earnings on March 13, which could provide further clarity on its financial position.

In other recent news, Century Therapeutics has been notified by The Nasdaq Stock Market LLC of a potential delisting due to its share price falling below the required minimum. The company has until August 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Meanwhile, Century Therapeutics has launched a Phase 1/2 trial, named CARAMEL, in collaboration with Friedrich-Alexander University Erlangen-Nürnberg, to evaluate its investigational cell therapy CNTY-101 for autoimmune diseases. This trial aims to assess the safety and efficacy of the therapy, which targets conditions like systemic lupus erythematosus and lupus nephritis.

In analyst ratings, Piper Sandler has maintained an Overweight rating on Century Therapeutics, though it lowered its price target from $12 to $4. This adjustment reflects recent corporate updates and clinical trial progress. Additionally, Clear Street initiated coverage on Century Therapeutics with a Buy rating and a price target of $9.00, citing the potential of the company’s iPSC platform and Allo-Evasion technology. The company also faced a setback with Bristol-Myers Squibb (NYSE:BMY) ending their collaboration on developing therapies for acute myeloid leukemia and multiple myeloma. Despite this, Century Therapeutics remains optimistic about its scientific advancements and plans to continue exploring opportunities in these areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.